AM281

Research use only, not for human use.

AM 281, a cannabinoid antagonist, reduces neurologic dysfunction and mortality rate after cecal ligation and puncture in rats.

AM281 is a synthetic cannabinoid CB1 receptor antagonist.

——

Animal Model:Male NMRI mice with the weight of 25-30 gDosage:0.62, 1.25 and 2.5 mg/kg (chronic administration); 2.5, 5 and 10 mg/kg (acute administration) Administration:Administrated i.p. every day concurrently with morphine except the day of experiment (chronic administration); Singly injected 40 min before second trial (acute administration)Result:The simultaneous daily administration of AM281 with morphine significantly shortened the exploration time, as compared with morphine-dependent mice receiving vehicle. Acute administration at a dose of 5 mg/kg, significantly augmented recognition index.

AM281 | AM 281 | AM-281

Microbiology/Virology

HCV

CB

——

——

202463-68-1

557.21

C21H19Cl2IN4O2

>98% (HPLC)

In Vitro:?DMSO : 7.14 mg/mL (12.81 mM)

Ic1ccc(c2n(nc(c2C)C(=O)NN2CCOCC2)c2c(Cl)cc(Cl)cc2)cc1

1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholin-4-ylpyrazole-3-carboxamide

(-20℃)

With Ice Pack

≥ 2 years